Medical Condition News

RSS

INEN, MD Anderson sign sister institution agreement

The University of Texas MD Anderson Cancer Center today signed a sister institution agreement with the National Cancer Institute of Peru. Also known as the Instituto Nacional de Enfermedades Neoplásicas, INEN is Peru's sole national referral center for cancer.

18 Mar 2011

Quest Diagnostics ColoVantage molecular colorectal cancer detection test receives New York State approval

Quest Diagnostics Incorporated, the world's leading cancer diagnostics company, today announced that its ColoVantage test has been approved by New York State's Department of Health for testing on samples of patients in the state. It is believed to be the first molecular colorectal cancer detection method that employs a venal blood specimen to be approved by the state.

From Quest Diagnostics 18 Mar 2011

BUSM scientists identify new biomarker and melanoma treatment target

Researchers at Boston University School of Medicine, in collaboration with Johns Hopkins University, have identified a potential new biomarker and therapeutic target for melanoma.

18 Mar 2011

FibroGen, Astellas advance FG-4592 to phase 2b development for treatment of anemia in chronic kidney disease

FibroGen, Inc., today announced that FibroGen and partner Astellas Pharma Inc. advanced FG-4592 (Astellas designation ASP1517), an investigational anemia therapy, to phase 2b development for treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.

18 Mar 2011

ACT initiates enrollment in TEMPASURE cardiac ablation catheter CE Mark clinical trial

Advanced Cardiac Therapeutics, Inc., a developer of innovative temperature-sensing cardiac ablation systems, today announced that the first patients have been enrolled in a first-in-man CE Mark clinical trial of the safety and performance of the company's TEMPASURE™ cardiac ablation catheter. The TEMPASURE system is the world's first RF cardiac ablation catheter to offer both saline irrigation and temperature-sensing technology.

17 Mar 2011

Low calorie diet may delay or prevent aging and neurodegenerative diseases

Cells, which employ a process called autophagy to clean up and reuse protein debris leftover from biological processes, were the original recyclers. A team of scientists from Paul Greengard's Rockefeller University laboratory have linked a molecule that stimulates autophagy with the reduction of one of Alzheimer's disease's major hallmarks, amyloid peptide.

17 Mar 2011

FDA grants CSI marketing clearance for Stealth 360° Orbital PAD System

Cardiovascular Systems, Inc. has received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA), and has begun a limited market release for the Stealth 360°™ Orbital PAD System. The Stealth 360° propels CSI into the forefront of treating peripheral arterial disease (PAD) with a simpler design that gives physicians complete control of device operation.

17 Mar 2011

CytRx commences INNO-206 Phase 1b trial in advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has initiated an open-label Phase 1b safety and dose escalation clinical trial with INNO-206 at the Sarcoma Oncology Center in Santa Monica, California. The clinical trial will include up to 24 patients with advanced solid tumors who have failed standard therapies.

17 Mar 2011

APS ACTION brings experts together to improve patient outcomes

Motivated by the lack of treatment options for patients with antiphospholipid syndrome, rheumatology researchers convened an international committee to address the problem directly.

17 Mar 2011

Research on electrophysiological assessment of hearing in patients with acoustic neuromas

Manuel Don, Ph.D., is a principal investigator in the Division of Communication and Auditory Neuroscience at the House Ear Institute. Dr. Don joined the House Ear Institute in 1976 after working as an assistant research auditory physiologist at the University of California, Irvine.

17 Mar 2011

Special report takes critical look at debates about pediatric problematic moods, behaviors

Decisions about whether and how to diagnose children with emotional and behavioral disturbances, and whether and how to treat them, are sometimes not clear-cut. When decisions lie within a "zone of ambiguity," people who emphasize different value commitments can reach different but equally respectable conclusions.

17 Mar 2011

TF3 consortium receives ECCH contract to provide RNTI

The TF3 consortium has been chosen to provide a Remote Telemonitoring Service to Northern Ireland which will support over 8,000 patients during the course of the contract.

17 Mar 2011

Kentucky Governor signs license bill to practice diabetes education

Kentucky Governor Steve Beshear signed a bill yesterday that requires a license to practice diabetes education, a move that the American Association of Diabetes Educators says will enhance consumer protection and increase professional recognition.

17 Mar 2011

Major breakthrough in thrombosis

Scientists from the University of Reading have announced a major breakthrough in understanding how to control blood clotting which could lead to the development of new treatments and save the lives of thousands of people each year.

17 Mar 2011

Highmark forces patients with PIDD to switch over to specific IgG therapy

Beginning April 1, Highmark Blue Cross Blue Shield will force their insured patients with primary immunodeficiency diseases and other rare disorders to switch their prescription to a single brand of immunoglobulin, regardless of their current IgG therapy.

17 Mar 2011

Experts to review latest research on bariatric surgery at International summit

On March 28, leading experts across multiple disciplines will convene at the 2nd World Congress on Interventional Therapies for Type 2 Diabetes to review the latest research on bariatric surgery as a treatment option.

17 Mar 2011

pIMAGO nanopolymer can test cancer drug efficacy against biochemical processes

A Purdue University scientist's nanopolymer would make it easier and cheaper for drug developers to test the effectiveness of a widely used class of cancer inhibitors.

17 Mar 2011

Inovio signs agreement with OncoSec to sell non-DNA cancer vaccine technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has signed an agreement with OncoSec Medical Inc. providing for the sale to OncoSec of certain non-DNA vaccine technology and intellectual property relating to electroporation technology useful for electrochemical and cytokine based immune therapies for treating solid tumors.

17 Mar 2011

PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting

PsiOxus Therapeutics, Ltd. announced initiation of a Phase II study of MT-102, a small molecule therapeutic for the treatment of cancer- and age-related wasting. MT-102 is being developed to reverse the effects of cachexia, a wasting disease that accompanies cancer, heart failure, COPD, renal failure, cirrhosis and rheumatoid arthritis, and that is associated with significant morbidity and mortality.

17 Mar 2011

Scientist suggests breaking tangled mucus barrier can help treat cancer

Measuring the mechanical strength of cancer cell mucus layers provides clues about better ways to treat cancer, and also suggests why some cancer cells are more resistant to drugs than others, according to Kai-tak Wan, associate professor of engineering at Northeastern University, Boston, Mass.

17 Mar 2011

Medical Condition News

INEN, MD Anderson sign sister institution agreement

Quest Diagnostics ColoVantage molecular colorectal cancer detection test receives New York State approval

BUSM scientists identify new biomarker and melanoma treatment target

FibroGen, Astellas advance FG-4592 to phase 2b development for treatment of anemia in chronic kidney disease

ACT initiates enrollment in TEMPASURE cardiac ablation catheter CE Mark clinical trial

Low calorie diet may delay or prevent aging and neurodegenerative diseases

FDA grants CSI marketing clearance for Stealth 360° Orbital PAD System

CytRx commences INNO-206 Phase 1b trial in advanced solid tumors

APS ACTION brings experts together to improve patient outcomes

Research on electrophysiological assessment of hearing in patients with acoustic neuromas

Special report takes critical look at debates about pediatric problematic moods, behaviors

TF3 consortium receives ECCH contract to provide RNTI

Kentucky Governor signs license bill to practice diabetes education

Major breakthrough in thrombosis

Highmark forces patients with PIDD to switch over to specific IgG therapy

Experts to review latest research on bariatric surgery at International summit

pIMAGO nanopolymer can test cancer drug efficacy against biochemical processes

Inovio signs agreement with OncoSec to sell non-DNA cancer vaccine technology

PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting

Scientist suggests breaking tangled mucus barrier can help treat cancer

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Latest News